Production (Stage)
Cidara Therapeutics, Inc.
CDTX
$24.28
-$1.42-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -99.04% | 277.13% | |||
| Gross Profit | 99.04% | -277.13% | |||
| SG&A Expenses | -15.45% | 47.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -53.36% | 211.50% | |||
| Operating Income | 53.36% | -211.50% | |||
| Income Before Tax | 55.16% | -237.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 55.16% | -237.10% | |||
| Earnings from Discontinued Operations | -- | 113.78% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 55.11% | -227.23% | |||
| EBIT | 53.36% | -211.50% | |||
| EBITDA | 53.39% | -212.00% | |||
| EPS Basic | 69.20% | -119.66% | |||
| Normalized Basic EPS | 69.24% | -126.29% | |||
| EPS Diluted | 69.20% | -119.58% | |||
| Normalized Diluted EPS | 69.24% | -126.29% | |||
| Average Basic Shares Outstanding | 45.74% | 48.97% | |||
| Average Diluted Shares Outstanding | 45.74% | 48.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||